PBL 7 Session 3

Get Started. It's Free
or sign up with your email address
Rocket clouds
PBL 7 Session 3 by Mind Map: PBL 7 Session 3

1. Step 9

1.1. Review session 2

1.2. mechanism flow chart

1.2.1. neurodegenrative

1.2.2. TRAP

1.2.3. basala ganglia is affected

1.2.4. dupamine depletion

1.2.5. extrapyramidle dysfunction

1.3. 20 minutes

2. Step 10

2.1. Management

2.1.1. goals of treatment

2.1.1.1. increasing the level of dupaine

2.1.1.2. reliefe the symptoms

2.1.1.3. delay the progression of the disease

2.1.1.4. avoiding side effects

2.1.1.5. treatment variability

2.1.1.6. maintaining quilty of life

2.1.2. depend on the age and stage of disease

2.1.3. start when disability appear or other need to start the treatment

2.1.4. pharma

2.1.4.1. L-dopa

2.1.4.1.1. precursor of dupamine

2.1.4.1.2. cross BBB

2.1.4.1.3. side effect of dupa in perphri

2.1.4.1.4. with carbidopa to prevent caroxylase

2.1.4.1.5. 5-10% circulate as dopamine in perphri

2.1.4.1.6. asbortion

2.1.4.1.7. with anti emetic only dompredene

2.1.4.1.8. neurones retain dupa to sometimes

2.1.4.1.9. used above of 65-70 year and more sever stage

2.1.4.1.10. benserezide as alternative of carbidopa

2.1.4.1.11. peak-dose-dyskinesia

2.1.4.2. dopamine agonst

2.1.4.2.1. used in early stage as monotherapy

2.1.4.2.2. or in compination

2.1.4.2.3. more side effect

2.1.4.2.4. less motor flucciuation

2.1.4.2.5. work on D1, D2, and 35

2.1.4.2.6. not selective

2.1.4.2.7. ergot and non- ergot

2.1.4.2.8. indicated in younger patients

2.1.4.2.9. impuls control disorder

2.1.4.2.10. with patient cogntive still intact

2.1.4.2.11. shouldnt drive

2.1.4.2.12. dupamine withdrawal syndrome

2.1.4.3. entacapone

2.1.4.3.1. block the breackdown

2.1.4.4. amantadine

2.1.4.5. seleginie

2.1.4.5.1. liver failure

2.1.4.6. apomorphine

2.1.4.6.1. subcutanious

2.1.4.7. anticholinergic

2.1.4.7.1. for tremor

2.1.4.7.2. contrainticate4d in elderly

2.1.4.8. l-dopa inistinal gel

2.1.5. non- pharma

2.1.5.1. surgical

2.1.5.1.1. deep brain stimulation

2.1.5.1.2. stem cells of putamin

2.1.5.2. pallitaive care

2.1.5.3. education

2.1.5.4. referral if any other symptoms persist

2.1.5.5. dietrition

2.1.5.5.1. low protein anf fat

2.2. Prevention

2.2.1. nicotine

2.2.1.1. not sure

2.2.2. caffene

2.3. 60 minutes

3. step 11

3.1. Review and evaluate

3.2. Group members

3.3. Chairman

3.4. Scribe

3.5. Tutor

3.6. Material

3.7. 10 minutes